Dosage of antipseudomonal antibiotics in patients with acute kidney injury subjected to continuous renal replacement therapies;Dosificación de antibióticos antipseudomónicos en pacientes con disfunción renal aguda sometidos a técnicas continuas de depuración extrarenal

Medicina Intensiva

Volumn 37, Issue 3, 2013, Pages 185-200

  Carcelero San Martin E ^a   Soy Muner, D ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Acute kidney injury; Antibiotics; Continuous renal replacement therapies; Pseudomonas spp.

Indexed keywords

ANTIBIOTIC AGENT;

ACUTE KIDNEY FAILURE; ANTIBIOTIC THERAPY; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; EARLY INTERVENTION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; PSEUDOMONAS INFECTION; SEPSIS; SHORT SURVEY;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; HUMANS; PSEUDOMONAS INFECTIONS; RENAL REPLACEMENT THERAPY; THIENAMYCINS;

EID: 84876704604     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2012.02.012     Document Type: Short Survey

References (49)

1. Vincent J.L., Rello J., Marshall J., Silva E., Anzueto A., Martin C.D., et al. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
2. Bueno-Cavanillas A., Delgado-Rodríguez M., López-Luque A., Schaffino-Cano S., Gálvez-Vargas R. Influence of nosocomial infection on mortality rate in an intensive care unit. Crit Care Med 1994, 22:55-60.
3. Clermont G., Acker C.G., Angus D.C., Sirio C.A., Pinsky M.R., Johnson J.P. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int 2002, 62:986-996.
4. Uchino S., Kellum J.A., Bellomo R., Doig G.S., Morimatsu H., Morgera S., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818.
5. Joy M., Matzke G., Amstrong D., Marx M.A., Zarowitz B.J. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998, 32:362-375.
6. Zucchelli P., Santoro A. Dialysis-induced hypotension. A fresh look at pathophysiology. Blood Purif 1993, 11:85-98.
7. Pea F., Viale P., Pavan F., Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007, 46:997-1038.
8. Mouton J.W., Vinks A.A. Is continuous infusion of beta-lactam antibiotics worthwhile?-Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996, 38:5-15.
9. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
10. Mueller S.C., Majcher-Peszynska J., Hickstein H., Francke A., Pertschy A., Schulz M., et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002, 46:1557-1560.
11. Capellier G., Cornette C., Boillot A., Guinchard C., Jacques T., Blasco G., et al. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit Care Med 1998, 26:88-91.
12. Arzuaga A., Maynar J., Gascón A.R., Isla A., Corral E., Fonseca F., et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005, 45:168-176.
13. Valtonen M., Tiula E., Takkunen O., Backman J.T., Neuvonen P.J. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001, 48:881-885.
14. Traunmüller F., Schenk P., Mittermeyer C., Thalhammer-Scherrer R., Ratheiser K., Thalhammer F. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother 2002, 49:129-134.
15. Mariat C., Venet C., Jehl F., Mwewa S., Lazarevic V., Diconne E., et al. Continuous infusión of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care 2006, 10:R26.
16. Sato T., Okamoto K., Kitaura M., Kukita I., Kikuta K., Hamaguchi M. The pharmacokinetics of ceftazidime during hemodiafiltration in critically ill patients. Artif Organs 1999, 23:143-145.
17. Isla A., Gascón A.R., Maynar J., Arzuaga A., Sánchez-Izquierdo J.A., Pedraz J.L. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy 2007, 53:194-201.
18. Allaouchiche B., Breilh D., Jaumain H., Gaillard B., Renard S., Saux M.C. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 1997, 41:2424-2426.
19. Isla A., Gascón A.R., Maynar J., Arzuaga A., Toral D., Pedraz J.L. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther 2005, 27:599-608.
20. Malone R.S., Fish D.N., Abraham E., Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001, 45:3148-3155.
21. Tegeder L., Bremer F., Oelkers R., Schobel H., Schuttler J., Brune K., et al. Pharmacokinetics of imipenem-cilastatin incritically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother 1997, 41:2640-2645.
22. Fish D.N., Teitelbaum I., Abraham E. Pharmacokinetics and Pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005, 49:2421-2428.
23. Thalhammer F., Schenk P., Burgmann H., El Menyawi I., Hollenstein U.M., Rosenkranz A.R., et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998, 42:2417-2420.
24. Tegeder I., Neumann F., Bremer F., Brune K., Lötsch J., Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999, 65:50-57.
25. Ververs T.F., Van Dijk A., Vinks S.A., Blankestijn P.J., Savelkoul J.F., Meulenbelt J., et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 2000, 28:3412-3416.
26. Krueger W.A., Neeser G., Schuster H., Schroeder T.H., Hoffmann E., Heininger A., et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 2003, 49:280-286.
27. Bilgrami I., Roberts J.A., Wallis S.C., Thomas J., Davis J., Fowler S., et al. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother 2010, 54:2974-2978.
28. Meyer M.M., Munar M.Y., Kohlhepp S.J., Bryant R.E. Meropenem Pharmacokinetics in a Patient with multiorgan failure from meningococcemia undergoing continuous venovenous hemodiafiltration. Am J Kidney Dis 1999, 33:790-795.
29. Isla A., Maynar J., Sánchez-Izquirdo J.A., Gascón A.R., Arzuaga A., Correal E., et al. Meropenem and Continuous Renal Replacement Therapy: in vitro permeability of 2 Continuous Renal Replacement Therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol 2005, 45:1294-1304.
30. Giles L.J., Jennings A.C., Thomson A.H., Creed G., Beale R.J., McLuckie A. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000, 28:632-637.
31. Valtonen M., Tiula E., Backman J.T., Neunoven P.J. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2000, 45:701-704.
32. Krueger W.A., Schroeder T.H., Hutchison M., Hoffmann E., Dieterich H.J., Heininger A., et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998, 42:2421-2424.
33. Robatel C., Decosterd L.A., Biollaz J., Eckert P., Schaller M.D., Buclin T. Pharmacokinetics and dosage adaptation of meropenem duronc continuous venovenous hemofiafiltration in critically ill patients. J Clinical Pharmacol 2003, 43:1329-1340.
34. Langgartner J., Vasold A., Glück T., Reng M., Kees F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 2008, 34:1091-1096.
35. Ohchi Y., Hidaka S., Goto K., Shitomi R., Nishida T., Abe T., et al. Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration. Yakugaku Zasshi 2011, 131:1395-1399.
36. Barrie J.R., Mousdale S. Ciprofloxacin levels in a patient undergoing veno-venous haemodiafiltration. Intensive Care Med 1992, 18:437-438.
37. Malone R.S., Fish D.N., Abraham E., Teitelbaum I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001, 45:2949-2954.
38. Wallis S.C., Mullany D.V., Lipman J., Rickard C.M., Daley P.J. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med 2001, 27:665-672.
39. Utrup T.R., Mueller E.W., Healy D.P., Callcut R.A., Peterson J.D., Hurford W.E. High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. Ann Pharmacother 2010, 44:1660-1664.
40. Hansen E., Bucher M., Jakob W., Lemberger P., Kees F. Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. Intensive Care Med 2001, 27:371-375.
41. Traunmüller F., Thalhammer-Scherrer R., Locker G.J., Losert H., Schmid R., Staudinger T., et al. Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. J Antimicrob Chemother 2001, 47:229-231.
42. Fuhrmann V., Schenk P., Jaeger W., Ahmed S., Thalhammer F. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 2004, 54:780-784.
43. Robert R., Rochard E., Malin F., Bouquet S. Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med 1991, 19:588-589.
44. Spooner A., Corrigan O., Donnelly M. Pharmacokinetic basis for improving therapeutic outcomes of aminoglycoside therapy during continuous venovenous haemodiafiltration. Crit Care 2007; 1, Suppl. 2. P101.
45. Li J., Rayner C.R., Nation R.L., Deans R., Boots R., Widdecombe N., et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005, 49:4814-4815.
46. Alvarez Lerma F., Sierra Camerino R., Alvarez Rocha L., Rodríguez Colomo O. Antibiotic policy in critical patients. Med Intensiva 2010, 34:600-608.
47. Sörgel F., Kinzig M. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med 1994, 20(Suppl 3):S14-S20.
48. Soy D., Badia J.R., Torres A. Antibiotic dosage regimens in respiratory tract infections in the pharmacokinetic/pharmacodynamic era. Curr Respir Med Rev 2006, 2:89-97.
49. López E., Soy D., Codina C., Ribas J. Algunas reflexiones acerca de la administración de antibióticos β-lactámicos en infusión continua. Enferm Infecc Microbiol Clin 2006, 24:445-452.